Foundation Medicine Developing Targeted Sequencing Test for 'Clinically Actionable' Cancer Genes

The company is currently using the test, which analyzes several hundred cancer genes in tumors, in a pilot collaboration with Novartis and plans other partnerships with pharmaceutical firms and academic medical centers to demonstrate its analytical validity and clinical utility.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.